Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. (RXRX) priced its initial public offering on Apr 16, 2021 at $18.00 per share, within its $16.00–$18.00 range, raising $436.4M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.92B. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan, BofA Securities and Leerink Partners and others. Wilson Sonsini advised the company and Davis Polk advised the underwriters.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines biology, chemistry, automation, data science and engineering in its Recursion OS to speed drug discovery. It advances internally developed programs, including clinical-stage assets, and builds large biological and chemical datasets.

Status

IPO

Ticker

RXRX

Exchange

Nasdaq Global Select

Priced

Apr 16, 2021

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$436.4M

Market cap at IPO price

$2.92B

First filed

Mar 22, 2021

Underwriters

Goldman Sachs, J.P. Morgan, BofA Securities, Leerink Partners, Allen & Company and KeyBanc

Company counsel

Wilson Sonsini

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

UT

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.